Plus Therapeutics Inc Stock News

Non-dilutive payment is part of $17.6 million award granted for the Company's leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) canc...

Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Lab Improvement Amendments (CLIA) HOUSTON, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeut...

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on...

HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it received a letter (the “Letter”) from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 55...

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical com...

HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the “Equity ...

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...

CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations